Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

This is an Open Access article that has been identified as being free of known restrictions under copyright law, including all related and neighboring rights (https://creativecommons.org/publicdomain/mark/1.0/). You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission.

PMC Copyright notice

Figure 1. — Schematic diagram of N-809, PD-L1 binding, and effects of N-809 on the proliferation and activity of CD4 and CD8 T cells. (a) Illustration of N-809, a bifunctional molecule created by fusing two single chain human anti-PD-L1 domains to an IL-15 superagonist scaffold with an IgG1 Fc portion. (b) Binding of N-809 to PD-L1⁺ H441 cells was analyzed by flow cytometry using APC labeled antibody specific for the Fc portion of hIgG. (c, d) Healthy donor CD4 and CD8 T cells were stimulated with plate-bound anti-CD3 and increasing concentrations of N-809. Fold change represents the change from untreated (0 ng/ml), anti-CD3 stimulated T cells for one representative donor. (e) Tumor cell lysis by an HPV E7-specific T cell line grown in the presence or absence of N-809 (37.5 ng/ml). Results of a lysis assay using CaSki (cervical carcinoma) cells as targets at a 10:1 E:T ratio is shown. MDA-MB-231 (breast carcinoma) cells were used as a control to determine specificity of the lysis. **P < 0.01.